Design Therapeutics Q2 net loss $7.6M; FA GeneTAC on track for H1 2022 clinical start

Design Therapeutics, Inc.

2022-Q2 EPS reported -$0.36

Net loss $7.6M; R&D expenses $5.0M, G&A $2.7M; cash & investments $402.8M.
Lead FA GeneTAC program: IND-enabling data support initiation of Phase 1 trial in H1 2022.
Appointed Elizabeth Gordon, Ph.D., as SVP Regulatory Affairs; board expanded with Behanna & Prasad.
DM1 GeneTAC program preclinical data planned for H2 2021.
Well-tolerated FA GeneTAC doses in rodents/NHPs achieved CNS, heart, muscle concentrations above therapeutic threshold.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.